期刊文献+

胰岛素脂质混悬液肺部给药的生物利用度及对肺部损伤的初步考察 被引量:12

Study on the bioavailability and initial investigation on the rat following pulmonary delivery of insulin lipid suspension
下载PDF
导出
摘要 目的 研究胰岛素脂质混悬液(ILS)经正常大鼠气管滴注给药后肺部吸收的生物利用度,并对给药造成的肺损伤进行初步考察。方法 以薄膜-超声分散法制备ILS,结合药效学和药动学考察气管滴注给药后的药理相对生物利用度和药物相对生物利用度;以肺水肿指数和肺组织病理改变为指标考察肺部给药后对肺部造成的损伤。结果ILS以1、4、8u/kg肺部给药后其药理相对生物利用度分别为65.2%、50.8%和37.1%,药物相对生物利用度分别为67.9%.40.9%和31.7%,均随给药剂量增加而降低;连续7d气管滴注给药后,ILS给药组的肺水肿指数和肺组织病理改变与普通胰岛素溶液给药后相比具有显著性差异,前者优于后者并接近正常组。结论ILS肺部给药后可达到较高的生物利用度。 Purpose To study the bioavailability of pulmonary administered insulin lipid suspension (ILS) in normal rats and to investigate the damage to the lung after administration. Methods ILS was prepared by thin-film sonication method. Following intratracheally instillation of ILS, the relative pharmacological bioavailability (f % ) and relative bioavailability ( F % ) of ILS were calculated based on the area above the curve (AAC) and the area under the curve (AUC) compared with subcutaneous injection of insulin PBS, respectively. The changes of pulmonary edema index and pathology of lungs were investigated to evaluate the severity of the damage to lungs. Results As ILS was administered at different doses (1,4,8u/kg), the f % values reached 65.2 %,50.8 % and 37.1 %, respectively, and the F % values reached 67.9 %,40.9 % arid 31.7 % , separately. The results showed that the following intratracheally instillation for 7 consecutive days, the pulmonary edema index and pathological changes of lung tissue in ILS group were significantly different from those in regular insulin solution group and close to those in normal one. Conclusion The results showed that ILS could achieve higher bioavailability and reduce the severity of damage to rat lung following pulmonary delivery.
出处 《中国生化药物杂志》 CAS CSCD 2002年第6期271-274,共4页 Chinese Journal of Biochemical Pharmaceutics
基金 教育部优秀青年教师资助计划(1779) 教育部回国人员启动基金(2001) 上海市卫生局科技发展基金(01409)
关键词 胰岛素脂质混悬液 肺部给药 生物利用度 肺部损伤 insulin lipid suspension intratracheallv installation bioavailability
  • 相关文献

参考文献7

  • 1Kisel MA, Kulik LN, Tsybovsky, et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: study in the rat [J]. Int J Pharm, 2001, 216:105-114.
  • 2Smith PL. Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery [J]. J Control Release, 1997, 46: 99-106.
  • 3Patton J. Breathing life into protein drugs [J]. Nature Biotechnol, 1998, 16: 141-143.
  • 4Haitsma JJ, Lachmann U, Lachmann B. Exogenous surfactant as a drug delivery agent [J]. Adv Drug Deliv Rev, 2001, 47(2-3): 197-207.
  • 5Adjei AL, Gupta PK. Inhalation Delivery of Therapeutic Peptides and Proteins [M]. New York: Marcel Dekker, 1997. 667-702.
  • 6江志强,胡天喜,马远鸣,奚念朱.防治成人呼吸窘迫综合征的人工重组肺泡表面活性剂研制II.生物发光法筛选制剂处方[J].药学学报,1997,32(2):123-126. 被引量:4
  • 7江志强,吕剑.胰岛素脂质混悬液的肺部给药[J].药学学报,2002,37(5):378-382. 被引量:16

二级参考文献6

  • 1李益新,上海免疫学杂志,1985年,5卷,25页
  • 2顾学裘,中草药,1982年,13卷,157页
  • 3江志强,中国药学杂志,1995年,30卷,增刊,103页
  • 4胡天喜,发光分析与医学,1991年
  • 5李海丽,发光学报,1988年,9卷,249页
  • 6沈赞聪,张强,崔纯莹,魏树礼.胰岛素气雾剂经大鼠肺部给药的生物利用度[J].药学学报,2000,35(6):465-468. 被引量:7

共引文献17

同被引文献175

引证文献12

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部